O-RAN ALLIANCE Announces New Specifications and Demos, First Open Test and Integration Centers and Its June 29 Industry Summit
O-RAN ALLIANCE welcomes stc as its new operator member, building up the world-wide community of 29 mobile network operators committed to deployment of open and intelligent Radio Access Networks (RAN).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005961/en/
O-RAN Logical Architecture (Graphic: Business Wire)
33 New or Updated O-RAN Specifications Released since March 2021
On June 17, 2021, the O-RAN ALLIANCE published another 33 specification documents, including 11 new titles. Among others these new specifications include:
- Management interface, timing and synchronization for Transport
- The baseline for Non-Real-Time Radio Intelligent Controller (Non-RT RIC) and Near-Real-Time RIC Architecture and interfaces (E2, A1, F1/X2/Xn)
- Certification and badging guidelines and parts of end-to-end, inter-operability and conformance testing
For more details on the new specifications, please check this O-RAN blog post. To download O-RAN specifications, please proceed to www.o-ran.org/specifications.
First European Open Test and Integration Centers Hosted by Deutsche Telekom and TIM
The O-RAN ALLIANCE approved the first two European Open Test and Integration Centers (OTIC):
- European OTIC in Berlin hosted by Deutsche Telekom
- European OTIC in Torino hosted by TIM
OTICs provide a collaborative, open, and impartial working environment to ensure consistency and quality of testing of O-RAN products and solutions.
“It is great to see the momentum in adoption of O-RAN based solutions,” said Alex Jinsung Choi, COO of the O-RAN ALLIANCE and SVP Technology Strategy & Technology Innovation, Deutsche Telekom. “OTICs will play an important role in managing the complex interoperability scenarios and related integration cost, and accelerate O-RAN product commercialization in large network solutions.”
36 New O-RAN Demonstrations
O-RAN ALLIANCE is excited to announce the release of 36 demos to be showcased at the O-RAN Virtual Exhibition by June 29, 2021. Five of these demos will also be presented at the MWC Barcelona exhibition by:
- Parallel Wireless at Hall 5, Booth 515
- Rohde & Schwarz at Hall 6, Booth B30
- Sageran, presenting 3 demos at Hall 7, Booth 7N50
More companies are presenting their demos in the virtual form: Analog Devices, Arm, Astri, Baicells, Capgemini, China Mobile, CIG, Comba Telecom, H3C, Intel, IS-Wireless, ITRI, Juniper Networks, Keysight, Lenovo, NEC, Netcracker, Nokia, Nvidia, NXP, O-RAN Software Community, Parallel Wireless, Pegatron, Radisys, Rohde & Schwarz, Qualcomm, Sageran, Siemens EDA, TIM, T&W, VIAVI Solutions, WindRiver.
For more details on these demos, please read our blog post.
O-RAN ALLIANCE Industry Summit on June 29, 2021
O-RAN ALLIANCE plans to hold its next Industry Summit on June 29th. The 90 minute live virtual session will provide exclusive insights from top executives that are driving the rapid advances in the O-RAN space. During the panel discussion speakers from AirHop Communications, AT&T, Deutsche Telekom, Facebook, Mavenir, Nokia, Rakuten Mobile, TIM, VIAVI and VMware will share their views on key topics including Open RAN Commercialization, Open RAN Security and Performance. The summit will conclude with a live Q&A where the audience can submit their questions for the panelists. Join the event at www.o-ran.org/events.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005961/en/
Contact information
O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Exclusive Coverage of ReActiv8 ® by Anthem Blue Cross/Blue Shield28.4.2025 15:30:00 EEST | Press release
Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. The coverage went into effect on April 16, 2025, and expands access to the procedure, when clinically appropriate, to Anthem’s policyholders. “We have been on a 17-year mission to prove the value of ReActiv8 through careful and thorough research,”said Jason Hannon, CEO of Mainstay Medical.“We have made a commitment to developing a large body of robust clinical and real-world evidence proving the efficacy and safety of the therapy in an indication where patients are desperately seeking durable solutions. We are pleased to see a leading payer like Anthem recognize the evidence we have built, and we look forward to discussing
Kraken Offers US Securities Through Strategic Partnership with Alpaca28.4.2025 15:30:00 EEST | Press release
Kraken, one of the world’s most trusted and longest-standing cryptocurrency platforms with more than 15 million global clients, now offers US securities to US-residing clients. By expanding their product offering, Kraken continues to bridge the gap between digital and traditional assets– furthering their position as an institutional grade, multi-asset-class trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428924377/en/ Kraken has launched this new asset class through a strategic partnership with Alpaca– an API-first brokerage platform and self-clearing broker-dealer for stocks, ETFs, and options who serves hundreds of financial services and millions of brokerage accounts around the world. Through this partnership, Kraken is offering its users access to a large and diverse investable asset universe, combining their best-in-class crypto platform of more than 300 digital assets and 6 different fiat currencies
Philip Morris International CEO Jacek Olczak Addresses Emerging Global Divide in Regulatory Approaches to Consumer Innovation28.4.2025 15:15:00 EEST | Press release
Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (NYSE: PM), outlined the need for common-sense regulations in the consumer goods sector while addressing global leaders at Semafor’s annual World Economy Summit in Washington, D.C., on April 25, 2025. Olczak emphasized the sector’s potential for innovation-led growth despite the volatile economic environment. He stressed, however, that without appropriate regulation and policy frameworks to enable scientific evaluation and consumer access, promising breakthroughs—such as innovations in wellness, food, and personal care products—could become missed opportunities. While addressing the tobacco and nicotine industry specifically, Olczak stated, “Disparities in nicotine regulation are creating a global divide with profound health and economic impacts. Some countries that have prohibited smoke-free products are seeing higher smoking rates persist, while many of those whose policies encourage smokers to make better choi
HistoSonics’ Histotripsy System Demonstrates 90% Local Tumor Control at 12 Months in #HOPE4LIVER Trials28.4.2025 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison Histotripsy System, announced today 12-month follow-up clinical data from its prospective #HOPE4LIVER trials, designed to evaluate the safety and efficacy of histotripsy for the non-invasive destruction of primary (hepatocellular cancer-HCC) and metastatic liver tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428931117/en/ The Edison System, which received U.S. Food and Drug Administration (FDA) De Novo clearance in October 2023, uses focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures. These latest data reinforce histotripsy’s potential to emerge as a new category of non-invasive therapy for patients suffering from liver tumors. The #HOPE4LIVER trials enrolled 47 patients across 14 centers in the United States, United Kingdom and Europe, with tumors either originating in the
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy28.4.2025 15:00:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly progressive and potentially fatal disease for which there are limited treatment options. Vutrisiran is currently approved in the European Union (EU) under the brand name AMVUTTRA® for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. ATTR-CM is caused by the deposition of misfolded transthyretin (TTR) fibrils, which drive progressive and irreversible cardiovascular damage and premature death. Vutrisiran is an RNAi therapeutic that works upstream to red
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom